In this issue:
IV drug use: no barrier to HCV therapy
Telaprevir improves HCV treatment response
High SVR with short telaprevir-based regimen
Telaprevir improves SVR rate in non-responders
New PIs for HCV prove cost-effective
Rising mortality from HCV in the USA
Please login below to download this issue (PDF)